Focus forward on R&D

Negative top-line result of phase III study and continued progress in other clinical projects

Capital raising characterizes NeuroVive ́s first quarter

Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...

Important outlicensing deal and increased focus on core operations

NeuroVive's research wins award at international research symposium

Successful rights issue and final patient treated in phase III study on CicloMulsion®

NeuroVive consolidates positioning as leading mitochondrial medicine company

Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators

Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...

The listing on Nasdaq OMX creates possibilities for the future